ACLX

NEUTRALM&A

Arcellx, Inc.

2026-03-31

Price

$114.82

+0.04%

Score5.9Watchlist

Signals6/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

The price action in Arcellx (ACLX) is entirely dictated by Gilead Sciences' $7.8 billion acquisition offer at $115 per share plus a $5 contingent value right. This definitive M&A catalyst perfectly explains the stock's microscopic 2.1% annualized volatility and the presence of SURGE and STEADY_CLIMB signals, as institutional arbitrageurs pin the price just below the cash offer. In the context of a CAUTION (GEOPOLITICAL) macro regime, ACLX acts as an ultimate safe-haven cash proxy, completely insulated from the bearish market tide. Conviction remains exceptionally high that the stock will hover near its $114.29 support until the deal officially closes or regulatory hurdles emerge.

Fired Signals

SURGEALPHA MALESTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEINSIDE OUT

Key Takeaways

Actionable Thesis: ACLX is a pure merger arbitrage play pinned to Gilead's $115/share cash offer, acting as a safe haven against broader market volatility [1.12].
Key Risk: Regulatory intervention or deal collapse is the sole structural threat, which would severely punish the stock and erase the M&A premium.
What to Watch: Monitor updates on the deal's closing timeline and any developments regarding the $5 Contingent Value Right (CVR) conditions.

← Back to 2026-03-31 View Full ACLX History →Yahoo Finance &nearr;